Published in Cancer Weekly, October 14th, 2003
The company issued approximately 2.5 million shares of its unregistered common stock, with 30% warrant coverage to purchase additional shares of its common stock at $1.25.
"We believe this funding will help further develop our promising HIV and cancer platforms," said Nicholas Jon Virca, CEO of Adventrx. "In less than 5 months, we were able to raise a second round of financing at more than twice the price of our last funding, reflecting the high expectations for our HIV trial of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.